Prot #GLPG1690: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects with Idiopathic P

Project: Research project

Project Details

Effective start/end date8/8/193/31/23


  • PPD Investigator Services, LLC (Prot #GLPG1690)
  • Galapagos NV (Prot #GLPG1690)